Mike Raab, Ardelyx
August 4, 2021 07:00 AM EDT
People
FDA+

Arde­lyx chops a third of its staff af­ter stock-crush­ing fail­ure in chron­ic kid­ney dis­ease

Nicole DeFeudis

Editor

A cou­ple of weeks af­ter the FDA turned down Arde­lyx’s chron­ic kid­ney dis­ease can­di­date, shock­ing an­a­lysts and CEO Mike Raab, the com­pa­ny is ax­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times